LiverRight and Aegle Medical Solutions, LLC have announced a strategic partnership aimed at expanding access to non-invasive liver assessment, specialist interpretation, diagnosis, and ongoing liver care for patients across the United States. The collaboration brings together Aegle Medical's advanced liver assessment technology and support services with LiverRight's national virtual liver clinic, creating a more connected pathway for healthcare organizations to identify and manage liver disease.
For physicians, health systems, and independent practices, the partnership is designed to simplify the establishment or expansion of comprehensive liver disease programs. Aegle Medical provides consultative technology evaluation, implementation, training, and ongoing support, including the Mindray Hepatus-Series Transient Elastography Diagnostic Ultrasound Systems. LiverRight offers same-day interpretation of liver elastography studies and same-week virtual access to its hepatology clinicians. The Liververse™ referral system coordinates bloodwork, patient-reported outcomes, imaging, diagnosis, and longitudinal disease management.
The collaboration addresses a critical gap in liver care. Many adults in the U.S. live with undiagnosed liver disease, and access to hepatology specialists can be limited, particularly in certain communities. By combining advanced assessment technology with virtual specialist expertise, the partnership aims to bring liver assessment closer to where patients already receive care. This model can help providers identify liver disease earlier, improve access to specialist expertise, and create a better experience for both patients and clinicians.
Central to the partnership is the Mindray Hepatus platform, which introduces Visualized Transient Elastography (ViTE), a next-generation advancement beyond conventional transient elastography. ViTE integrates real-time B-mode ultrasound visualization directly into the elastography examination, allowing operators to see liver anatomy, identify optimal measurement locations, and visually guide each acquisition while obtaining quantitative liver stiffness and attenuation measurements. This evolution combines the efficiency of transient elastography with the clinical confidence of real-time ultrasound visualization in a single examination.
Unlike legacy platforms that may require different probes based on patient body habitus, the Hepatus platform is designed to streamline examinations with a more efficient, B-mode image-guided workflow. It provides liver stiffness measurement (LSM) for fibrosis assessment and Liver UltraSound Attenuation (LiSA) for quantitative assessment of hepatic steatosis. The Hepatus 6 further expands capabilities by combining these features with diagnostic ultrasound imaging for abdominal imaging, Doppler, spleen stiffness assessment, and intestinal ultrasound, depending on configuration.
LiverRight's network includes hepatologists and hepatology advanced practice providers licensed across all 50 U.S. states, supporting adults with conditions such as MASLD/MASH, alcohol-associated liver disease, hepatitis B and C, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, and liver cancer diagnosis. The partnership allows health systems, GI and hepatology practices, and independent providers to offer a scalable approach to expanding liver services under their own brand.
Brandon Tudor, CEO of LiverRight, noted that Aegle Medical is helping hospital systems and independent practices address the significant number of adults with undiagnosed liver disease. Michael McTighe, President & CEO of Aegle Medical Solutions, emphasized that the partnership represents an important step forward in expanding access to liver disease detection and care, particularly in communities where access to hepatology specialists may be limited.
For more information about Aegle Medical Solutions, visit https://www.aeglemedicalsolutions.com. Additional details about LiverRight can be found at https://www.liverright.com.
